Katy Rezvani: Exciting research on CD70-targeting CAR NK cells

Katy Rezvani shared Elizabeth McKenna’s post on X, adding:

“Many congratulations to our Dr. Sunil Acharya for his exciting research on CD70-targeting CAR NK cells, published in Cancer Discovery!

Sunil and his co-authors showed that the incorporation of CD28 co-stimulation, which is normally absent in NK cells, in the CAR construct improves efficacy of CAR NK cells via the LCK/CD3ζ/ZAP70 pathway.

Sincere thanks to our collaborators for their invaluable contributions. We’re excited about the promising clinical trials ahead!”

Quoting  Elizabeth McKenna’s post:

“Now online in Cancer Discovery: CD28 Costimulation Augments CAR Signaling in NK cells via the LCK/CD3ζ/ZAP70 Signaling Axis – by Sunil Acharya, Katy Rezvani and colleagues.”

Source: Katy Rezvani/X  and Elizabeth McKenna/X

Elizabeth McKenna is the Executive Director of Cancer Discovery at the American Association for Cancer Research. Elizabeth earned her PhD from Harvard University and trained with Dr. Charles Roberts at the Dana-Farber Cancer Institute. Her research was among the first to show that pediatric tumors characterized by mutations in chromatin remodelers are genomically stable and instead driven by epigenetic deregulation of key target genes. She joined Cancer Discovery shortly after its launch as its founding Science Writer and became an editor in 2014, rising through the editorial ranks to become the journal’s Executive Editor in 2019. She is a member of the 40 Under 40 in Cancer Class of 2021.

Katy Rezvani, holds roles including Professor of Medicine, Director of Translational Research, and Chief of the Section of Cellular Therapy at MD Anderson Cancer Center. Previously, she directed stem cell transplant programs and research laboratories at Hammersmith Hospital, London. Dr. Rezvani’s research focuses on enhancing natural killer (NK) cell function against leukemia, utilizing genetic engineering techniques. Her work has led to funded Phase I/II trials in leukemia and lymphoma immunotherapy.